reteplase is a segment of tissue plasminogen activator used for the removal of thrombi in blood vessels. in the present study the cloned reteplase gene was used for its expression in competent e. coli. the  recombinant plasmid, pet15b/reteplase (rpet-bl21), was transformed into competent e.coli strain bl21 (de3) cells. overnight culture of the transformed bacteria was induced by the addition of...

Administration of intravenous reteplase might be a choice of treatment of acute ischemic stroke.

background: production of tissue plasminogen activator protein (t-pa) in prokaryotes systems has many problems such as the lack of active protein production, multiple purification steps, and renaturation process which has been shown to be costly and time-consuming. methods: in this study, reteplase which is the nonglycosylated active domain of t-pa was used to transform top10 escherichia coli (...

Coronary heart disease is the single largest cause of mortality in the UK with acute myocardial infarction (AMI) being responsible for the greatest amount of deaths. Improving perfusion to the myocardium to prevent further damage or death of the cardiac tissue is the aim of treating AMI. In the UK reperfusion is achieved either through the use of an thrombolytic agent (streptokinase, alteplase,...

BACKGROUND AND PURPOSE Early reocclusion of recanalized arteries has been observed after thrombolysis for acute coronary occlusion and has been attributed to platelet activation after exposure to thrombolytic agents. We conducted a retrospective study to determine the rate of reocclusion during intra-arterial thrombolysis for acute ischemic stroke and the effect of reocclusion on functional out...

We performed molecular dynamics simulations of Reteplase in the presence different excipients to study stabilizing mechanisms and identify role during freeze drying. To simulate freeze-drying process, we divided process into five distinct steps: (i) protein–excipient formulations at room temperature, (ii) ice-growth (iii)–(iv) partially solvated fully dried formulations, (v) reconstitution. Fur...

Thrombolytic therapy has been a major milestone in the management of acute myocardial infarction. By restoring patency in the infarct-related vessel, early administration of thrombolytic therapy reduces the extent of myocardial damage, lowers the risk of morbidity, and prolongs survival. Importantly, however, the available thrombolytic agents have several limitations that may result in less tha...

BACKGROUND Improvement of thrombolysis may be achieved by concomitant strong platelet inhibition. To monitor platelet function in patients with myocardial infarction (n=46) who were treated with the fibrinolytic agent reteplase, the glycoprotein (GP) IIb/IIIa blocker abciximab, and the ADP receptor antagonist ticlopidine, we developed a flow cytometric assay. METHODS AND RESULTS Binding of ab...